Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2561]

Highlights from APCCC 2026

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

Highlights from APCCC 2026 ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in bladder cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in bladder cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

ASCO 2026: Updates in renal cancer

Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires...

ASCO 2026: Updates in renal cancer ( Dr Natalia Gandur - Instituto de Oncología 'Ángel H. Roffo', Buenos Aires, Argentina )

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma

Prof Meletios Dimopoulos - National and Kapodistrian University of Athens...

Mezigdomide plus carfilzomib dexamethasone improves PFS in R/R multiple myeloma ( Prof Meletios Dimopoulos - National and Kapodistrian University of Athens, Athens, Greece )

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1...

Dr Chiara Sartor - University of Bologna, Bologna, Italy

Venetoclax azacitidine achieves MRD clearance and enables transplant in NPM1 mutated AML with molecular failure ( Dr Chiara Sartor - University of Bologna, Bologna, Italy )

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed...

Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA

DVRd improves MRD negativity and PFS in transplant ineligible newly diagnosed multiple myeloma ( Dr Saad Usmani - Memorial Sloan Kettering Cancer Center, New York City, USA )

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light...

Prof Ashutosh Wechalekar - University College London Hospitals, London, UK

Anselamimab reduces mortality and cardiovascular hospitalisation in kappa light chain AL amyloidosis ( Prof Ashutosh Wechalekar - University College London Hospitals, London, UK )

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R...

Prof Liang Wang - Beijing Tongren Hospital, Beijing, China

CD19 CD22 bispecific CAR T cell therapy achieves high response rates in R/R large B cell lymphoma ( Prof Liang Wang - Beijing Tongren Hospital, Beijing, China )

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute...

Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston...

Subcutaneous blinatumomab plus TKI drives high remission in relapsed Ph+ acute lymphoblastic leukaemia ( Prof Elias Jabbour - The University of Texas MD Anderson Cancer Center, Houston, USA )

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor...

Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany

ATG vs PTCy for GVHD prophylaxis in AlloHCT shows improved survival in donor haematopoietic cell transplantation ( Dr Johannes Schetelig - University Hospital TU Dresden, Dresden, Germany )

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue...

Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA)...

Arsenic trioxide plus all trans retinoic acid improves QoL and reduces fatigue in high risk acute promyelocytic leukaemia ( Prof Fabio Efficace - Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy )

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL...

Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA

Pirtobrutinib plus venetoclax rituximab improves PFS in previously treated CLL and SLL ( Dr Matthew Davids - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer